Rates of major complications during neoadjuvant and adjuvant chemotherapy for early breast cancer: An off study population.
To determine the incidence and risk factors for thromboembolic events (TE) and febrile neutropenia (FN) in patients receiving systemic chemotherapy for early breast cancer (EBC). 325 patients received FEC75, FEC100-T or ECaP for EBC in 2013. TE occurred in 7.4% and FN in 19.1% of patients. Risk factors for TE were: central venous catheter (p = 0.011). Risk factors for FN were: FEC100-T treatment versus FEC75 and ECaP (p ≤ 0.001); lower pre-treatment neutrophil count (p = 0.009) and poorer performance status (p = 0.012). Two patients died from treatment-related toxicities. In real-world experience, the majority of patients completed adequate treatment, despite significant complications.